US EditionNovo Nordisk, Pfizer Sweeten Bid for Metsera as Bidding War Heats Up
Pfizer alleges Novo Nordisk’s $6 billion bid to acquire Metsera violates antitrust law by eliminating a U.S. competitor in GLP-1 drug market, risking less competition for obesity treatments.
- On Monday, Pfizer filed a second antitrust lawsuit in the U.S. District Court in the District of Delaware, alleging Novo Nordisk's outbid is anticompetitive and naming Metsera's controlling stockholders as conspirators.
- On Thursday, Danish drugmaker Novo Nordisk launched a $9 billion takeover bid for Metsera, triggering a four-business-day deadline after Pfizer had agreed in September to acquire Metsera for $4.9 billion, rising to $7.3 billion with future payments.
- Metsera's pipeline shows a GLP-1 agonist and an amylin analogue ready for phase 3, and Pfizer pursued it as a shortcut to two late-stage candidates with $5 billion peak sales potential.
- The complaint argues that `Novo Nordisk's bid would produce anticompetitive effects`, and Pfizer says it is taking action to preserve competition, while Novo Nordisk did not immediately respond.
- Market observers say Pfizer's second suit alleges Metsera's controlling shareholders conspired with Novo Nordisk, raising stakes after Pfizer lost ground to Eli Lilly over the last year.
20 Articles
20 Articles
Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up
(Reuters) -Novo Nordisk and Pfizer have revised their bids for Metsera, the obesity drug developer said on Tuesday. Novo’s revised offer brings the deal value to about $10 billion, while Pfizer is now willing to shell out $8.1 billion. The revised bids come as both companies are engaged in a public dispute to acquire Metsera. Pfizer has filed two lawsuits against Metsera, its board, and Novo Nordisk. The first lawsuit, filed on Friday, claims No…
The conflict between the pharmaceutical giants Pfizer and Novo Nordisk expands, after Pfizer announced in months that he opened a second process against the Danish company and the US biotechnology developer Metsera. The complaint, from the Federal Court of Delaware, accused Novo Nordisk of anticompetitive behaviour in an attempt to win the competition for the purchase of Metsera, [...]
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
